Click to Share
 

Clinical Trial Press Releases

+ Alert
+ Feed
Exclusive News
Topics Locations Industries Dates

By Biosceptre International Limited
Biosceptre has initiated its Phase I clinical trial of the peptide vaccine BIL06v, with the first patient treated at the initial trial site on 16th of August 2018.
By XpertDox
XpertDox, a data analytics firm focused on improving healthcare outcomes for patients with serious and rare diseases, today announced that the University of Alabama at Birmingham (UAB), one of the largest academic medical centers in the United States,...
12711732
By Project Alive
Donation in honor of Hunter Syndrome advocate Simon Ibell who passed away in 2017 at the age of 39 due to complications from Hunter Syndrome
12682890
By Project Alive
Vector Production and Active IND Meet Major Milestones in Foundation-Scientists Collaboration to Develop an Experimental Therapy for Young Boys with a Rare Dementia-Like Disease
12681405
By www.biosceptre.com
Biosceptre has received over £8M into its series A raise which will be used to resource the next stage of the companies' development; progression into the clinic of Biosceptre's first systemic products against novel oncology target nfP2X7.
12654663
By Project Alive
Parents Trying to Help Fund a Cure For the Rare Disease Hunter Syndrome / MPS II
By Adtec Europe Limited
Clinical Trial to investigate the potential benefits of treating Actinic Keratosis with Adtec SteriPlas plasma technology.
12648948
By Project Alive
Parent Efforts Bringing Awareness to the Rare Disease Hunter Syndrome / MPS II
12633798
By Biosceptre International Ltd
Biosceptre's appointment of a CMO marks a major milestone in progression to the clinic of its therapeutic anticancer vaccine BIL06v against the novel oncology target nfP2X7.
By www.biosceptre.com
Biosceptre's proposed Phase I clinical trial for BIL03s (anti-cancer monoclonal antibody therapy) was granted conditional approval by the Bellberry Ethics committee.
12625728
By Carolinas Healthcare System
After eight years of trying to conceive on their own, a couple gets pregnant within three months of enrolling in an infertility trial at Carolinas HealthCare System's CMC Women's Institute.
By Stemedica International
Peer-reviewed Research Published in Nature's "Scientific Reports"
By Stemedica International
The Only Alzheimer's Disease Clinical Trial Using Stemedica's Ischemia-Tolerant Mesenchymal Stem Cells (itMSCs) Continues Recruitment at UCI
By Stemedica International
Latest preclinical data regarding the effects of Stemedica's proprietary stem cells on Alzheimer's disease to be publicized
12557019
By Biosceptre International Limited
Biosceptre announces today that Sir Gregory Winter, founder of Cambridge Antibody Technology, Domantis and a co-founder of Bicycle Therapeutics Limited has joined the Board as a non-executive Director.
12550866
By Forward Clinical Trials
Experimental drug shows promise for patients with extreme eczema
By Quotient Clinical
Quotient Clinical, the Translational Pharmaceutics® company, has expanded its clinical spray drying capability through the acquisition of a Niro Mobile Minor™ Spray Dryer.
By Stemedica International
Stemedica International, SA, a leader in the development of innovative stem cell-based treatments for Alzheimer’s Disease announced today that it has received IRB approval from Emory University in Atlanta, Georgia to initiate a clinical study entitled,...
By NuvOx Pharma
The FDA has notified NuvOx Pharma that it may proceed with a clinical trial for its Investigational New Drug (IND), NVX-508 for vaso-occlusive crisis (VOC) and acute chest syndrome (ACS) in sickle cell disease.
By eyeforpharma
The pharma industry is facing a considerable challenge in the clinical space: how to enhance data quality.

All Press Releases

By Cures Within Reach
Medical Repurposing Research Pitch Competition During the 'Collaborations Addressing Vulnerable Populations' Forum in Herndon, Virginia
By Greenphire
Continued growth and expanding market share lands global leader of clinical trial payment automation solutions prestigious recognition
By Biosceptre International Limited
Biosceptre has initiated its Phase I clinical trial of the peptide vaccine BIL06v, with the first patient treated at the initial trial site on 16th of August 2018.
By Greenphire
Greenphire, the global leader in financial software for clinical trials, today announced that it has received ISO 27001:2013 Certification for its Information Security Management System (ISMS).
By XpertDox
XpertDox, a data analytics firm focused on improving healthcare outcomes for patients with serious and rare diseases, today announced that the University of Alabama at Birmingham (UAB), one of the largest academic medical centers in the United States,...
12711732
By Project Alive
Donation in honor of Hunter Syndrome advocate Simon Ibell who passed away in 2017 at the age of 39 due to complications from Hunter Syndrome
By Salutaris Medical Devices, Inc
Salutaris Medical Devices, Inc. announces first subject treated in a clinical trial investigating the SMD-DA ophthalmic device for the treatment of neovascular Age-related Macular Degeneration (nAMD)
12682890
By Project Alive
Vector Production and Active IND Meet Major Milestones in Foundation-Scientists Collaboration to Develop an Experimental Therapy for Young Boys with a Rare Dementia-Like Disease
12681405
By www.biosceptre.com
Biosceptre has received over £8M into its series A raise which will be used to resource the next stage of the companies' development; progression into the clinic of Biosceptre's first systemic products against novel oncology target nfP2X7.
12654663
By Project Alive
Parents Trying to Help Fund a Cure For the Rare Disease Hunter Syndrome / MPS II
By Adtec Europe Limited
Clinical Trial to investigate the potential benefits of treating Actinic Keratosis with Adtec SteriPlas plasma technology.
12648948
By Project Alive
Parent Efforts Bringing Awareness to the Rare Disease Hunter Syndrome / MPS II
12633798
By Biosceptre International Ltd
Biosceptre's appointment of a CMO marks a major milestone in progression to the clinic of its therapeutic anticancer vaccine BIL06v against the novel oncology target nfP2X7.
By www.biosceptre.com
Biosceptre's proposed Phase I clinical trial for BIL03s (anti-cancer monoclonal antibody therapy) was granted conditional approval by the Bellberry Ethics committee.
12625728
By Carolinas Healthcare System
After eight years of trying to conceive on their own, a couple gets pregnant within three months of enrolling in an infertility trial at Carolinas HealthCare System's CMC Women's Institute.
By Stemedica International
Peer-reviewed Research Published in Nature's "Scientific Reports"
By Stemedica International
The Only Alzheimer's Disease Clinical Trial Using Stemedica's Ischemia-Tolerant Mesenchymal Stem Cells (itMSCs) Continues Recruitment at UCI
By Stemedica International
Latest preclinical data regarding the effects of Stemedica's proprietary stem cells on Alzheimer's disease to be publicized
By NuvOx Pharma
Evan Unger, MD, President and CEO of NuvOx, announced that the FDA has allowed an investigational new drug application (IND) for NVX-208 (dodecafluoropentane emulsion) to be tested in a Phase Ib trial in stroke patients.
12557019
By Biosceptre International Limited
Biosceptre announces today that Sir Gregory Winter, founder of Cambridge Antibody Technology, Domantis and a co-founder of Bicycle Therapeutics Limited has joined the Board as a non-executive Director.
By Quotient Clinical
Quotient Clinical, the Translational Pharmaceutics® company, and Upperton, the UK spray drying specialist, have announced a partnership to address drug delivery challenges.
12550866
By Forward Clinical Trials
Experimental drug shows promise for patients with extreme eczema
By Quotient Clinical
Quotient Clinical, the Translational Pharmaceutics® company, has expanded its clinical spray drying capability through the acquisition of a Niro Mobile Minor™ Spray Dryer.
By Stemedica International
Stemedica International, SA, a leader in the development of innovative stem cell-based treatments for Alzheimer’s Disease announced today that it has received IRB approval from Emory University in Atlanta, Georgia to initiate a clinical study entitled,...
By NuvOx Pharma
The FDA has notified NuvOx Pharma that it may proceed with a clinical trial for its Investigational New Drug (IND), NVX-508 for vaso-occlusive crisis (VOC) and acute chest syndrome (ACS) in sickle cell disease.
By eyeforpharma
The pharma industry is facing a considerable challenge in the clinical space: how to enhance data quality.
By SMi Group
SMi Group reports (07.01.2016, London): SMi caught up with key speaker Deborah Lee, VP of Clinical Development from INSYS Therapeutics, Inc.
By NuvOx Pharma
Tucson based pharmaceutical company NuvOx Pharma announced today that it has secured orphan drug designation from the FDA for its investigational radiosensitizer for glioblastoma multiforme.

Page: 1 Page updated every 10 minutes


Like PRLog?
9K2K1K
Click to Share